Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma

Durvalumab is an anti‐PD‐L1 monoclonal antibody approved for patients with locally advanced or metastatic urothelial carcinoma (UC) that has progressed after platinum‐containing chemotherapy. A population tumor kinetic model, coupled with dropout and survival models, was developed to describe longit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yanan, Narwal, Rajesh, Jin, ChaoYu, Baverel, Paul G., Jin, Xiaoping, Gupta, Ashok, Ben, Yong, Wang, Bing, Mukhopadhyay, Pralay, Higgs, Brandon W., Roskos, Lorin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873369/
https://www.ncbi.nlm.nih.gov/pubmed/29243222
http://dx.doi.org/10.1002/cpt.986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873369/
https://www.ncbi.nlm.nih.gov/pubmed/29243222
http://dx.doi.org/10.1002/cpt.986

Ejemplares similares